Tekturna
Links shared publicly online about this topic
Tekturna (aliskiren) — High Blood Pressure Treatment
tekturna.com — “Learn more about Tekturna (aliskiren), an innovative new blood pressure treatment that works differently from other medicines available today and targets a key source that may contribute to high blood pressure.” View full resource at tekturna.com
Most Recently Shared on May 18, 2009 at 11:40 pm By:
Ivan Oransky Doctor and Health Communicator
DeMonaco: Media hype story repeated itself with Tekturna http://www.tekturna.com/index.jsp #ahcjnyc
Tekturna fails to show heart attack benefit | InPharm
inpharm.com — “Tekturna fails to show heart attack benefit | InPharm” View full resource at inpharm.com
Most Recently Shared on March 17, 2010 at 12:30 pm By:
Pharmafocus Health News and Pharma
Tekturna fails to show heart attack benefit - Novartis’ hypertension treatment Tekturna has failed to show it helps... http://ow.ly/16Pehj
Tekturna HCT approved for first-line hypertension therapy - MPR
empr.com — “The FDA has approved an expanded indication for Tekturna HCT (aliskiren/hydrochlorothiazide tablets, from Novartis) to include initial therapy for patients with hypertension who are likely to need multiple drugs to achieve their blood pressure goals.” View full resource at empr.com
Most Recently Shared on July 21, 2009 at 3:42 pm By:
MPR News: Tekturna HCT approved for first-line hypertension therapy: The FDA has approved an expanded i.. http://bit.ly/LHzN
Comments of comparing Tekturna, Ramipril (study 6037093) - eHealthMe.com
ehealthme.com — “Is Ramipril 10 mg. an equal substitute for Tekturna 150 mg in terms of the dosage amount?” View full resource at ehealthme.com
Most Recently Shared on March 13, 2012 at 9:02 pm By:
Is Ramipril 10 mg. an equal substitute for Tekturna 150 mg in terms of the dosage amount? http://t.co/qTqfEUBJ
Tekturna satisfaction and usage data | Monitoring more than 900 patients | Drug safety information | MediGuard
mediguard.org — “Tekturna satisfaction and usage data | Monitoring more than 900 patients | Drug safety information | MediGuard” View full resource at mediguard.org
Most Recently Shared on May 9, 2011 at 9:17 pm By:
MediGuard.org Health Organization
More than 27% of #tekturna users are aged 45-60 ... http://tinyurl.com/4lmuekt
TEKTURNA HCT 150/12.5 (Aliskiren, Hydrochlorothiazide) drug information from MPR
empr.com — “TEKTURNA HCT 150/12.5 (Aliskiren, Hydrochlorothiazide) drug information for Hypertension from MPR including side effects, drug interactions, dosing, contraindications and precautions.” View full resource at empr.com
Most Recently Shared on October 22, 2009 at 6:36 am By:
MPR News: TEKTURNA HCT 150/12.5: Adults: added initial therapy. http://bit.ly/qbzDP
Novartis' Blood-Pressure Drug Tekturna: A Victim of Bad Timing | BNET Pharma Blog | BNET
industry.bnet.com — “Adding Novartis‘ (NVS) blood-pressure medication Tekturna (aliskiren) to standard medical therapy in patientsrecovering from a heart attack” View full resource at industry.bnet.com
Most Recently Shared on April 19, 2010 at 5:17 pm By:
Jim Edwards Health Communicator
Novartis' Blood-Pressure Drug Tekturna: A Victim of Bad Timing: Adding Novartis' blood-pressure medication Tekturn... http://bit.ly/bBMp9f
FDA approves Tekturna HCT as initial treatment in patients unlikely to achieve their blood pressure goal with a single agent
novartis.com — “Basel, July 21, 2009 - The US Food and Drug Administration (FDA) has approved Tekturna HCT (aliskiren and hydrochlorothiazide) tablets as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals. Tekturna HCT is a single-pill combination of Tekturna (aliskiren), the first and only approved direct renin inhibitor[1], and the diuretic hydrochlorothiazide (HCTZ), one of the most commonly used high blood pressure medications[5].” View full resource at novartis.com
Most Recently Shared on July 21, 2009 at 1:43 pm By:
eyeonfda Pharma and Health Lawyer
FDA approves Tekturna HCT® as initial treatment in pts unlikely to achieve blood pressure goal with a single agent http://bit.ly/AfNcA
PharmaLive: Novartis to Restructure US Business to Strengthen Competitive Position in Light of Loss of Diovan Patent and Announces Charge for Rasilez/Tekturna
pharmalive.com — “PharmaLive: Novartis to Restructure US Business to Strengthen Competitive Position in Light of Loss of Diovan Patent and Announces Charge for Rasilez/Tekturna” View full resource at pharmalive.com
Most Recently Shared on January 13, 2012 at 3:00 pm By:
PharmaLive Pharma and Health News
Novartis to Restructure US Business: http://t.co/7jAxEjgQ #pharma
Novartis drug fails to help after heart attack: study | Reuters
reuters.com — “ATLANTA (Reuters) - The addition of the Novartis blood pressure medicine Tekturna to current standard drugs in patients who had a heart attack failed to help prevent changes in the heart's shape and worsening” View full resource at reuters.com
Most Recently Shared on March 16, 2010 at 7:45 pm By:
Hisham Rana, MD Doctor and Physician
Study: Novartis drug Tekturna fails to help after heart attack http://bit.ly/9YuBkd - From American College of Cardiology meeting. #health
Novartis drug fails to help after heart attack: study | Reuters
reuters.com — “ATLANTA (Reuters) - The addition of the Novartis blood pressure medicine Tekturna to current standard drugs in patients who had a heart attack failed to help prevent changes in the heart's shape and worsening” View full resource at reuters.com
Most Recently Shared on March 16, 2010 at 12:11 pm By:
Novartis drug fails to help after heart attack: study: ATLANTA (Reuters) - The addition of the Novart... http://bit.ly/9USnie #health #news
Debate on aliskiren data
theheart.org — “Aliskiren, a new direct renin inhibitor, reduced blood pressure to a greater degree than one of the usually recommended first-line agents, hydrochlorothiazide, in a new study. But there are a number of criticisms of the trial, including the assertion that the diuretic is not the ideal comparator. (Schmieder RE et al. Circulation 2009; 119:417-425.)” View full resource at theheart.org
Most Recently Shared on January 19, 2009 at 4:33 pm By:
New data on aliskiren provoke debate http://tinyurl.com/a8d3u8
Novartis receives FDA approval of Tekamlo, a single-pill combination of aliskiren and amlodipine to treat high blood pressure
drugs.com — “Tekamlo (aliskiren and amlodipine) is used to treat high blood pressure. Includes Tekamlo side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on August 29, 2010 at 11:22 pm By:
FDA approves Tekamlo (aliskiren and amlodipine) to treat high blood pressure - http://bit.ly/cKmXHQ
Novartis Gains FDA Approval for Amturnide, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
drugs.com — “Amturnide (aliskiren, amlodipine and hydrochlorothiazide) is used to treat high blood pressure. Includes Amturnide side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on December 29, 2010 at 8:12 pm By:
Drugs and Devices OW OW Health
Novartis Gains FDA Approval for Amturnide, a Triple-Combination Pill to Treat High Blood Pressure in Patie... http://bit.ly/fyXi8b #drug
Novartis Gains FDA Approval for Amturnide, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
drugs.com — “Amturnide (aliskiren, amlodipine and hydrochlorothiazide) is used to treat high blood pressure. Includes Amturnide side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on December 29, 2010 at 7:41 pm By:
FDA Approves Amturnide, a Triple-Combination Pill to Treat High Blood Pressure - http://bit.ly/eyIMLr
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Featuring the top 3 experts for this topic
-
Ivan Oransky
Executive editor, Reuters Health; journalism adjunct, NYU; blogger, Embargo Watch and Retraction Watch; AHCJ treasurer; Zinfandel drinker.
-
Pharmafocus
Monthly pharmaceutical, biotech & healthcare news publication for Europe. For pharma & biotech jobs follow @inpharmjobs. Twitter accounts run by @dominic_tyer
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
Advertisement
